Diagnostic Hematology Specialist- Clonoseq
CurrentAdaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today received clearance from the FDA for its clonoSEQ assay to detect and monitor minimal residual disease (MRD) in blood or bone marrow from patients with.